Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Genentech-s-Emicizumab-for-Hemophilia-A-Meets-Primary-Endpoint-in-Phase-III-Study-23591300/?utm_source=whatsapp&utm_medium=social&utm_campaign=share